Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CIPLA APREMILAST apremilast 30 mg tablet blister pack - TGA Drug Approval Details

Approvals/TGA/CIPLA APREMILAST apremilast 30 mg tablet blister pack

Approved

STANDARD

CIPLA APREMILAST apremilast 30 mg tablet blister pack

Cipla Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: Dec 9, 2025
Approval ID: 3d16e5c03eebbdd9
Company: Cipla Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: 3d16e5c03eebbdd9
Product Name: CIPLA APREMILAST apremilast 30 mg tablet blister pack
Artg Id: 460187
Artg Name: CIPLA APREMILAST apremilast 30 mg tablet blister pack
Sponsor: Cipla Australia Pty Ltd
Company Detail Path: /organization/cipla-australia-pty-ltd
Artg Date: 2025-05-09
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

3d16e5c03eebbdd9

Type

Standard

Back to TGA Approvals